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Microglia and astrocytes express numerous members of the Toll-like receptor (TLR) family that are pivotal for recognizing
conserved microbial motifs expressed by a wide array of pathogens. Despite the critical role for TLRs in pathogen recognition,
when dysregulated these pathways can also exacerbate CNS tissue destruction. Therefore, a critical balance must be achieved to
elicit suﬃcient immunity to combat CNS infectious insults and downregulate these responses to avoid pathological tissue damage.
We performed a comprehensive survey on the eﬃcacy of various PPAR-γ agonists to modulate proinﬂammatory mediator release
from primary microglia and astrocytes in response to numerous TLR ligands relevant to CNS infectious diseases. The results
demonstrated diﬀerential abilities of select PPAR-γ agonists to modulate glial activation. For example, 15d-PGJ2 and pioglitazone
were both eﬀective at reducing IL-12 p40 release by TLR ligand-activated glia, whereas CXCL2 expression was either augmented
or inhibited by 15d-PGJ2,e ﬀects that were dependent on the TLR ligand examined. Pioglitazone and troglitazone demonstrated
opposingactions onmicroglial CCL2productionthatwere TLRligand-dependent. Collectively, thisinformationmaybe exploited
to modulate the host immune response during CNS infections to maximize host immunity while minimizing inappropriate
bystander tissue damage that is often characteristic of such diseases.
Copyright © 2008 Catherine Gurley et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Microglia and astrocytes participate in the genesis of innate
immune responses in the CNS parenchyma [1, 2]. Their
strategic placement at or near the blood-brain barrier likely
makes both glial types sentinel cells for surveying pathogen
entry in the CNS parenchyma. Indeed, both microglia
and astrocytes are capable of producing a wide range of
proinﬂammatory mediators in response to a diverse array of
microbial stimuli [3, 4]. Therefore, it is likely that resident
glia are pivotal for eliciting a local CNS inﬂammatory
response through the initial production of inﬂammatory
mediators, which in turn, leads to the recruitment of addi-
tional immune eﬀector cells from the peripheral circulation.
Toll-like receptors (TLRs) are a group of pattern
recognition receptors (PRRs) responsible for recognizing
conserved motifs expressed on broad classes of microbes
termed pathogen-associated molecular patterns (PAMPs)
[5, 6]. Typically, PAMPs represent structural or nucleic acid
motifs that are less likely to undergo mutation, ensuring
eﬃcientpathogenrecognitionwithalimitedreceptorarsenal
[7]. A total of 13 TLRs have been identiﬁed to date,
each conferring recognition of conserved motifs from large
subclasses of bacteria, viruses, yeast, and fungi [5–7]. In
addition,recentevidenceindicatesthatTLRsarealsocapable
of sensing endogenous ligands produced during stress or
injury referred to as danger-associated molecular patterns
(DAMPs)thatmayparticipateinautoimmuneinduction[8–
10]. Numerous TLRs have been identiﬁed on microglia and
astrocytes and both glial types are responsive to numerous
TLR ligands implicating their role in pathogen recognition
(reviewed in [11, 12]). In addition, recent evidence links
TLRs with the host response to CNS injury presumably via
recognition of endogenous “danger signals” since classical
microbial TLR ligands are not present (reviewed in [13–
15]). Since TLRs have been implicated in both infectious
and noninfectious diseases of the CNS (reviewed in [11,
13]), understanding their potential to inﬂuence the course2 PPAR Research
of neuroinﬂammation is paramount and under certain
conditions inappropriate TLR activation may contribute
to excessive tissue destruction. Therefore, modulating TLR
activity to achieve optimal beneﬁt for the host may be
a plausible strategy for minimizing tissue damage during
neuroinﬂammatory disorders.
A group of compounds with reported anti-inﬂammatory
eﬀects in several models of inﬂammation, including the
CNS, are ligands that interact with peroxisome proliferator-
activated receptor-gamma (PPAR-γ)[ 16–18]. PPAR-γ is
a member of the nuclear hormone receptor superfamily
of ligand-activated transcription factors that regulate the
expression of genes involved in reproduction, metabolism,
development, and immune responses [17, 19]. A wide array
of both natural and synthetic agonists for PPAR-γ have been
identiﬁed including the naturally occurring prostaglandin
metabolite 15d-PGJ2, thiazolidinediones (TZDs) a group of
synthetic PPAR-γ agonists used for the treatment of diabetes,
polyunsaturatedfattyacids,andcertainhighaﬃnitytyrosine
derivatives. With regard to the CNS, several PPAR-γ agonists
have been documented for their ability to attenuate both
microglial and astrocyte activation in response to a diverse
array of stimuli as well as impact the course of several
neurodegenerativediseases[16,18,20–25].Althoughweand
others have demonstrated that select PPAR-γ agonists are
potent inhibitors of TLR2 and TLR4 activation (PGN and
LPS, resp.) [23, 24, 26–29], a comprehensive examination of
the eﬀects of PPAR-γ agonists on a wide array of TLR ligands
is lacking. In addition, although several studies describing
the responses of microglia and astrocytes to TLR ligands
exist [30–34], no reports have systematically investigated
the ability of PPAR-γ ligands to modulate glial activation
in response to TLR signals. Therefore, the purpose of this
study was to deﬁne the actions of a panel of PPAR-γ
agonists on TLR ligand-induced activation of microglia and
astrocytes. Although within the same class of compounds,
not all PPAR-γ agonists shared similar regulatory properties
in response to various TLR ligands. Indeed, in some cases,
inﬂammatory mediator production was enhanced following
PPAR-γ agonist treatment. Collectively, these results suggest
selectiveactionsofPPAR-γ agonistsonglialresponsestoTLR
ligands that could be exploited for speciﬁc neuroinﬂamma-
tory/infectious conditions of the CNS.
2. MATERIALS AND METHODS
2.1. TLRligandsandPPAR-γ agonists
The following TLR agonists were used in this study (see
Table 1) with the concentration of each and its TLR tar-
get identiﬁed in parenthesis: Pam3CSK4 (TLR2, 1μg/ml),
polyinosine-polycytidylic acid (polyI:C; TLR3, 25μg/ml),
lipopolysaccharide from E. coli O111:B4 (LPS; TLR4,
100ng/ml), ﬂagellin from Salmonella typhimurium (TLR5,
10μg/ml), single-stranded RNA (ssRNA; TLR7/8, 10μg/ml),
and synthetic unmethylated CpG oligonucleotide (ODN;
TLR9, 0.1μMa n d5μM for microglia and astrocytes, resp.).
All TLR ligands were obtained from InvivoGen (San Diego,
Calif, USA).
The natural PPAR-γ agonist 15d-PGJ2 and synthetic
TZDs ciglitazone, rosiglitazone, pioglitazone, and troglita-
zone were purchased from Cayman Chemical (see Table 2;
PPAR-γ Pak;AnnArbor,Mich,USA).Dose-responsestudies
were performed for all TZDs (10, 30, and 100μM) and 15d-
PGJ2 (5,10,and20μM)inbothTLR-activatedmicrogliaand
astrocytes.
2.2. Primarymicrogliaandastrocytecultures
Primary microglia and astrocytes were isolated from
C57BL/6 pups (2 to 4days of age) as previously described
[35, 36]. The purity of glial cultures was evaluated by
immunohistochemical staining using antibodies against
CD11b (BD Pharmingen) and glial ﬁbrillary acidic pro-
tein (GFAP, Invitrogen, Carlsbad, Calif, USA) to identify
microglia and astrocytes, respectively. The purity of primary
microglia and astrocyte cultures was approximately 98% and
95%, respectively.
Throughout this study, microglia and astrocytes were
seeded into 96-well plates at 2 × 105 or 1 × 105 cells/well,
respectively, and incubated overnight. The following day,
glia were pretreated with various PPAR-γ agonists for 1
hour prior to stimulation with the TLR ligand panel for
24hours. Cell-conditioned supernatants were collected at
24hours following TLR ligand treatment for quantitation of
proinﬂammatory mediator expression by ELISA.
2.3. Cellviabilityassays
The eﬀects of PPAR-γ and TLR agonists on glial cell viability
were evaluated using a standard MTT assay based upon
the mitochondrial conversion of (3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyltetrazolium bromide) (MTT) into formazan
crystals. Results are reported as the raw OD570 values
(mean±SD).
2.4. Enzyme-linkedimmunosorbentassays(ELISAs)
Protein levels of TNF-αandCXCL2(MIP-2)(Biosource)and
IL-12 p40 and CCL2 (MCP-1, OptEIA, BD Pharmingen, San
Jose, Calif, USA) were quantiﬁed in conditioned medium
from PPAR-γ and TLR ligand-treated glia using ELISA
kits according to the manufacturer’s instructions (level of
sensitivity = 15.6pg/ml).
2.5. Nitriteassay
Nitritelevels,astableendproductresultingfromthereaction
of NO with molecular oxygen, were determined in astro-
cytes by adding 50μl of cell-conditioned culture medium
with 50μl of Griess reagent (0.1% naphtyletylenediamine
dihydrochloride, 1% sulfanilamide, 2.5% phosphoric acid,
all from Sigma) in a 96-well plate. The absorbance at 550nm
was measured on a plate reader (Spectra Max 190, Molecular
Devices, Sunnyvale , Calif , USA), and nitrite concentrations
were calculated using a standard curve with sodium nitrite
(NaNO2, Sigma, level of sensitivity, 0.4μM). Based on our
previous ﬁndings where S. aureus-derived TLR ligands wereCatherine Gurley et al. 3
Table 1: Summary of PPAR-γ eﬀects on PAMP-activated microglia reported in this study.
TLR ligand
PPAR-γ agonist Pam3Cys polyI:C LPS Flagellin ssRNA ODN
15d-PGJ2
↓ IL-12 ↓ IL-12 ↓ IL-12 ↓ IL-12 ↓ IL-12 ↓ IL-12
↓ TNF-α ↓ TNF-α ↓ TNF-α ↓ TNF-α TNF-α ND∗ ↓ TNF-α
↓ CXCL2 ↑ CXCL2 ↑ CXCL2 No eﬀect CXCL2 No eﬀect CXCL2 ↑ CXCL2
↓ CCL2 ↓ CCL2 ↓ CCL2 ↓ CCL2 No eﬀect CCL2 ↓ CCL2
Rosiglitazone
↓ IL-12 ↓ IL-12 ↓ IL-12 ↓ IL-12 ↓ IL-12 ↓ IL-12
↓ TNF-α ↓ TNF-α No eﬀect TNF-α ↓ TNF-α TNF-α ND No eﬀect TNF-α
Pioglitazone
↓ IL-12 ↓ IL-12 ↓ IL-12 ↓ IL-12 ↓ IL-12 ↓ IL-12
↑ CXCL2 ↑ CXCL2
∗ND; not detectable.
Table 2: Summary of PPAR-γ eﬀects on PAMP-activated astrocytes reported in this study.
TLR ligand
PPAR-γ agonist Pam3Cys polyI:C LPS Flagellin ssRNA ODN
↓ IL-12 ↓ IL-12 ↓ IL-12 ↓ IL-12 ↓ IL-12 ↓ IL-12
15d-PGJ2 ↑ CXCL2 ↓ NO ↓ NO
↑ CXCL2
Ciglitazone ↓ CXCL2 ↓ CXCL2 ↓ CXCL2 ↓ CXCL2 NR∗ ↓ CXCL2
Pioglitazone
↓ IL-12 ↓ IL-12 ↓ IL-12 ↓ IL-12 ↓ IL-12 ↓ IL-12
↑ CXCL2 ↑ CXCL2 ↑ CXCL2
↑ CCL2 ↑ CCL2
Troglitazone ↓ CCL2 ↓ CCL2 NR ↓ CCL2 NR ↓ CCL2
∗NR: not reported.
potent inducers of NO in astrocytes but not microglia [24,
33, 34], we only quantitated NO levels in the former in the
current study.
2.6. Statistics
Signiﬁcant diﬀerences between experimental groups were
determined by the Student’s t-test at the 95% conﬁdence
interval using SigmaStat (SPSS Science, Chicago, Ill, USA).
In this study, we performed a minimum of two inde-
pendent replicates of each experiment to conﬁrm the results
obtained. The reporting of our results as representative
of “x” number of independent experiments was required
s i n c ei ti sd i ﬃcult to achieve identical levels of proinﬂam-
matory mediator expression with distinct preparations of
primary glia. As a result, the absolute concentrations of
the various proinﬂammatory mediators diﬀered between
individual experiments; however, the trends were consistent.
This required us to report results from a single study
where each experimental treatment was represented by 3-
4 individual wells (i.e., biological replicates) and statistical
analysis conducted.
3. RESULTS
3.1. AbilityofPPAR-γ agoniststomodulate
microglialcytokineproductioninresponseto
diverseTLRligands
Microglia represent the main innate immune eﬀector in
the CNS parenchyma as evident by their expression of
numerous TLRs [32, 37, 38]. Although much emphasis has
been placed on the neurodestructive properties of activated
microglia, recent studies have revealed that in the correct
context microglia can also facilitate CNS repair [39–41].
Therefore, striking the correct balance between regulated
and inappropriate microglial activation may lead to optimal
outcomes for a wide range of CNS neuroinﬂammatory
conditions. To determine whether PPAR-γ agonists could
serve to modulate microglial activation in the context of
CNS infection, the eﬀects of these compounds on microglial
cytokine production in response to diverse TLR ligands
were examined. The natural PPAR-γ agonist 15d-PGJ2 was
uniformly found to inhibit IL-12 p40 release in response to
all TLR ligands tested including Pam3Cys4, polyI:C, LPS,
ﬂagellin, ssRNA, and ODN (Figure 1). Fairly comprehensive
reductions in IL-12 p40 production were also observed with
all TLR ligands tested in response to the synthetic PPAR-γ
agonists rosiglitazone (Figure 2) and pioglitazone (Figure 3)
although the extent of inhibition was dramatically less
compared to 15d-PGJ2. Rosiglitazone exhibited signiﬁcant
toxicity to primary microglia at the highest dose tested
(i.e., 100μM), hence it was not included in the ﬁnal
analysis. In contrast, ciglitazone did not dramatically aﬀect
IL-12 p40 production in response to the majority of TLR
ligands examined (data not shown). Troglitazone exhibited
microglial toxicity at the two highest doses of agonist tested
(i.e., 100 and 30μM); therefore, the results of this PPAR-γ
agonist on microglial mediator production in response to
TLR ligands are not presented.4 PPAR Research
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Figure 1: The natural PPAR-γ agonist 15d-PGJ2 is a potent inhibitor of microglial IL-12 p40 production in response to a vast array of TLR
ligands. Primary microglia were plated at 2×105 cells/well in 96-well plates and incubated overnight. The following day, cells were pretreated
for 1hour with the indicated concentrations of 15d-PGJ2 prior to the addition of TLR ligands. Cell-conditioned supernatants were collected
at24hoursfollowingTLRligandexposure,whereuponIL-12p40levelsweredeterminedbyELISA(a).Theeﬀectsof15d-PGJ2 onmicroglial
viability were assessed using an MTT assay (b). Signiﬁcant diﬀerences between microglia treated with TLR ligands alone versus TLR ligands
+ 15d-PGJ2 are noted with asterisks (∗∗P<. 001). Results presented are representative of two independent experiments.
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Figure 2:ThesyntheticPPAR-γ agonistrosiglitazoneattenuatesIL-12p40productioninresponsetoTLRligandsinmicroglia.Primarymicroglia
were plated at 2 × 105 cells/well in 96-well plates and incubated overnight. The following day, cells were pretreated for 1hour with the
indicated concentrations of rosiglitazone prior to the addition of TLR ligands. Cell-conditioned supernatants were collected at 24hours
followingTLRligandexposure,whereuponIL-12p40levelsweredeterminedbyELISA(a).Theeﬀectsofrosiglitazoneonmicroglialviability
were assessed using an MTT assay (b). Signiﬁcant diﬀerences between microglia treated with TLR ligands alone versus TLR ligands +
rosiglitazone are noted with asterisks (∗P<. 05). Results presented are representative of two independent experiments.Catherine Gurley et al. 5
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Figure 3:TheTZDpioglitazoneinhibitsmicroglialIL-12p40expressioninresponsetodiverseTLRligands.Primarymicrogliawereplatedat2×
105 cells/well in 96-well plates and incubated overnight. The following day, cells were pretreated for 1hour with the indicated concentrations
ofpioglitazonepriortotheadditionofTLRligands.Cell-conditionedsupernatantswerecollectedat24hoursfollowingTLRligandexposure,
whereupon IL-12 p40 levels were determined by ELISA (a). The eﬀects of pioglitazone on microglial viability were assessed using an MTT
assay(b).SigniﬁcantdiﬀerencesbetweenmicrogliatreatedwithTLRligandsaloneversusTLRligands+pioglitazonearenotedwithasterisks
(∗P<. 05; ∗∗P<. 001). Results presented are representative of two independent experiments.
Another proinﬂammatory cytokine with potent eﬀects
on the blood-brain barrier as well as glial activation is TNF-
α [42]. This cytokine is expressed at high levels in numerous
CNS infectious diseases including bacterial meningitis, brain
abscess, as well as viral infections [43–46]. In some cases,
excessive TNF-α production during these infectious diseases
has been implicated in contributing to bystander damage
to surrounding host tissue [45, 46]. Therefore, strategies
aimed at achieving optimized cytokine expression may prove
beneﬁcial for favorable disease outcomes. Of the PPAR-γ
agonists tested, 15d-PGJ2 was found to exert the most global
inhibition of TNF-α production in response to the battery
of TLR ligands tested (Figure 4). Speciﬁcally, TNF-α release
by microglia in response to Pam3Cys4, polyI:C, ﬂagellin,
and ODN was signiﬁcantly attenuated by 15d-PGJ2,w h e r e a s
cytokine production following LPS treatment was not as
dramatically aﬀected. Single-stranded RNA (ssRNA) was a
poor inducer of TNF-α by primary microglia (Figure 4).
Similar to results with IL-12 p40, rosiglitazone was the next
more global inhibitor of TNF-α production in response to
the TLR ligands tested (Figure 5), whereas the other PPAR-
γ agonists (i.e., ciglitazone and pioglitazone) were largely
without eﬀect (data not shown). Collectively, these results
indicate that not all PPAR-γ agonists are equally eﬀective at
modulating proinﬂammatory cytokine release from primary
microglia and suggest that tailored responses to speciﬁc
pathogen motifs may be achieved through the use of distinct
PPAR-γ agonists.
3.2. PPAR-γ agonistsdifferentiallyaffect
chemokinereleasebymicrogliafollowingTLR
ligandtreatment
Chemokines are small molecular weight (8–14kDa) chemo-
tactic cytokines that are produced locally at sites of inﬂam-
mation and establish a concentration gradient resulting
in the active recruitment of target cell populations [47].
Chemokinesareastructurallyandfunctionallyrelatedfamily
of proteins subdivided into four groups based on the relative
position of conserved N-terminal cysteine residues [47–49].
In general, the chemokine subfamilies show similar, often
overlapping speciﬁcity with regards to the movements of the
target cell populations they orchestrate. One key chemokine
involved in the recruitment of neutrophils into areas of
inﬂammation, including the CNS, is CXCL2 (MIP-2) [50–
52].Theeﬀectsof15d-PGJ2 onmicroglialCXCL2expression
were complex and varied with each TLR ligand. Specif-
ically, CXCL2 release was either enhanced (polyI:C, LPS,
and ODN), reduced (Pam3Cys4), or remained unchanged
(ﬂagellin and ssRNA) (Figure 6). Increases in CXCL2 pro-
duction were also observed following pioglitazone treatment
in Pam3Cys- and ODN-stimulated microglia (Figure 7).
The overall stimulatory activity of 15d-PGJ2 on CXCL2
production is in agreement with reports from other groups
[53, 54].
Another chemokine that is associated with mononu-
clear cell inﬁltration during various CNS infections is6 PPAR Research
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Figure 4: The potency of 15d-PGJ2 to attenuate TNF-α production
variesaccordingtotheTLRligandexamined.Primarymicrogliawere
platedat2×105 cells/wellin96-wellplatesandincubatedovernight.
The following day, cells were pretreated for 1hour with the
indicated concentrations of 15d-PGJ2 prior to the addition of TLR
ligands. Cell-conditioned supernatants were collected at 24hours
following TLR ligand exposure, whereupon TNF-α levels were
determined by ELISA. Signiﬁcant diﬀerences between microglia
treated with TLR ligands alone versus TLR ligands + 15d-PGJ2 are
noted with asterisks (∗P<. 05; ∗∗P<. 001). Results presented are
representative of two independent experiments.
CCL2 (MCP-1), which targets monocyte and lymphocyte
entry [52, 55, 56]. Unlike CXCL2, which was diﬀerentially
regulated by 15d-PGJ2 in response to diverse TLR ligands,
CCL2 production was uniformly and potently attenuated by
this PPAR-γ agonist in response to the full array of TLR
ligands tested (Figure 8). Similar to IL-12 p40 production,
the synthetic TZDs demonstrated diﬀerential eﬀects on
CCL2 release from TLR ligand activated microglia. Specif-
ically, rosiglitazone was fairly comprehensive in its ability
to attenuate CCL2 production with signiﬁcant reductions
observed in response to Pam3Cys4, polyI:C, LPS, ﬂagellin,
and ODN, whereas the other TZDs tested (ciglitazone and
pioglitazone) did not have much eﬀect on CCL2 release
in response to the majority of TLR ligands tested (data
not shown). In summary, these results reveal that PPAR-
γ agonists display a wide range of eﬀects on chemokine
production by microglia elicited by TLR ligands.
3.3. EffectsofPPAR-γ agonistsonastrocytic
proinﬂammatorymediatorproductionin
responsetoTLRligands
Astrocytes participate in CNS innate immune responses
as evident by their ability to produce a wide array of
inﬂammatory mediators in response to diverse stimuli [1, 4].
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Figure 5: The synthetic PPAR-γ agonist rosiglitazone selectively
inhibits microglial TNF-α expression in response to TLR ligands.
Primary microglia were plated at 2 ×105 cells/well in 96-well plates
and incubated overnight. The following day, cells were pretreated
for 1hour with the indicated concentrations of rosiglitazone prior
to the addition of TLR ligands. Cell-conditioned supernatants were
collected at 24hours following TLR ligand exposure, whereupon
TNF-α levels were determined by ELISA. Signiﬁcant diﬀerences
between microglia treated with TLR ligands alone versus TLR
ligands + rosiglitazone are noted with asterisks (∗P<. 05). Results
presented are representative of two independent experiments.
As already mentioned, these molecules can have dramatic
consequences on CNS infection and tissue damage with
net eﬀects dictated by factors such as timing and duration
of release. To determine the eﬀects of PPAR-γ agonists
on astrocyte responses to TLR ligands, we examined the
production of two proinﬂammatory mediators produced
by activated astrocytes, namely, NO and IL-12 p40. Both
polyI:C and LPS were capable of reproducibly inducing NO
expression in astrocytes as previously described [31, 57],
which was attenuated by 15d-PGJ2 in a dose-dependent
manner (Figure 9). Similar inhibitory eﬀects on astrocytic
NO release in response to polyI:C and LPS were observed
with troglitazone and ciglitazone, whereas rosiglitazone and
pioglitazone did not modulate NO production (data not
shown). Of note was the fact that unlike microglia, which
exhibitedsigniﬁcantcelldeathinresponsetothehighestdose
of 15d-PGJ2 tested (i.e., 20μM), astrocyte viability was not
adversely aﬀected by 15d-PGJ2 at any of the concentrations
examined.Thisﬁndingisinagreementwithpreviousreports
demonstrating that, in general, primary astrocytes are more
refractory to the toxic eﬀects of PPAR-γ agonists compared
to primary microglia [23, 24, 27].
Similar to the ﬁndings obtained with microglia, 15d-
PGJ2 was a universal and potent inhibitor of IL-12 p40
productionbyastrocytesinresponsetoallTLRligandstestedCatherine Gurley et al. 7
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Figure 6: 15d-PGJ2 demonstrates diﬀerential eﬀects on CXCL2
production by microglia, which are TLR ligand-dependent. Primary
microglia were plated at 2 × 105 cells/well in 96-well plates and
incubated overnight. The following day, cells were pretreated for
1hour with the indicated concentrations of 15d-PGJ2 prior to
the addition of TLR ligands. Cell-conditioned supernatants were
collected at 24hours following TLR ligand exposure, whereupon
CXCL2 levels were determined by ELISA. Signiﬁcant diﬀerences
between microglia treated with TLR ligands alone versus TLR
ligands + 15d-PGJ2 are noted with asterisks (∗P<. 05; ∗∗P<
.001). Results presented are representative of two independent
experiments.
(Figure 10). In addition, both pioglitazone and troglitazone
were capable of attenuating IL-12 p40 expression in response
tothefullarrayofTLRligandsexamined(Figure 11anddata
not shown), whereas the eﬀects of ciglitazone were variable.
3.4. PPAR-γ agonistsmodulatechemokineproduction
byastrocytesfollowingTLRligandexposure
Although astrocytes are capable of releasing cytokines in
response to diverse antigens, they are often considered the
major source of chemokines during CNS inﬂammation [1,
4].Similartoourrecentreport,15d-PGJ2 slightlyaugmented
CXCL2 production by astrocytes in response to several
TLR ligands examined, namely Pam3Cys4, PGN, and LPS
(Figure 12 and data not shown) [24]. Similar increases in
CXCL2 release following PPAR-γ a g o n i s te x p o s u r eh a v ea l s o
been reported by others [53, 54]. In contrast, each synthetic
TZD appeared to diﬀerentially regulate CXCL2 release. For
example,ciglitazoneinhibitedCXCL2expressioninresponse
to the entire battery of TLR ligands examined (Figure 13).
Conversely, pioglitazone signiﬁcantly augmented CXCL2
expression in response to polyI:C, ﬂagellin, and ssRNA
particularly at the highest dose examined (i.e., 100μM;
Figure 14), whereas rosiglitazone did not dramatically alter
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2 × 105 cells/well in 96-well plates and incubated overnight. The
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CXCL2 levels response to any of the TLR ligands tested in
astrocytes (data not shown).
Similar to CXCL2, pioglitazone treatment increased
CCL2 production in response to ﬂagellin, and ssRNA pri-
marily at the highest dose tested, whereas troglitazone led to
signiﬁcant reductions in CCL2 release following Pam3Cys4,
polyI:C, ﬂagellin, and ODN treatment (Figure 15). In gen-
eral, ciglitazone and rosiglitazone had little eﬀect on CCL2
production by astrocytes in response to the majority of
TLR ligands tested (data not shown). These results indicate
that despite their inclusion within the same family, speciﬁc
PPAR-γ agonists diﬀerentially target proinﬂammatory genes
in distinct manners.
4. DISCUSSION
In order for the CNS to respond to infectious insults, a rapid
and eﬃcient host immune response must be initiated and
directed to expedite pathogen elimination. One means to
achieve this goal is through the triggering of TLRs expressed
on resident glia that signal proinﬂammatory mediator
release in an attempt to quell infection [11, 12]. However,
recent evidence also suggests that these normally protective
immune responses can become dysregulated, culminating8 PPAR Research
0
1000
2000
3000
4000
5000
6000
[
C
C
L
2
]
(
p
g
/
m
l
)
U
n
s
t
i
m
.
P
a
m
3
C
y
s
4
P
o
l
y
I
:
C
L
P
S
F
l
a
g
e
l
l
i
n
s
s
R
N
A
O
D
N
TLR ligand
(−) 15d-PGJ2
5μM 15d-PGJ2
10μM 15d-PGJ2
∗∗
∗∗
∗∗ ∗∗
∗∗ ∗∗
∗∗
∗
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in the destruction of surrounding normal CNS parenchyma
[13]. Therefore, ﬁne tuning the resultant immune response
to achieve maximal pathogen clearance concomitant with
minimal tissue damage would represent a best case scenario
for the management of a wide array of CNS infectious
diseases including bacterial meningitis, HIVE, brain abscess,
and other viral infections. The purpose of this study was to
perform a comprehensive analysis of the ability of several
PPAR-γ agonists to regulate glial activation in response to a
panel of TLR ligands that may be encountered during native
CNS infections. It is envisioned that this information may
be exploited as a ﬁrst step towards the derivation of speciﬁc
treatment strategies that could be implemented with existing
therapies for CNS infections to maximize beneﬁt to patients.
One obvious distinction between the various PPAR-
γ agonists tested to modulate TLR-dependent glial acti-
vation was the ﬁnding that 15d-PGJ2 consistently led to
more dramatic and widespread decreases in inﬂammatory
mediator production compared to the synthetic TZDs. This
relationship was observed with both primary microglia and
astrocytes and is in agreement with previous reports by
us and other laboratories where 15d-PGJ2 exerted potent
inhibitory eﬀects at lower eﬀective concentrations compared
to TZDs, despite the fact that the former exhibits a lower
binding aﬃnity to PPAR-γ [26, 27, 58, 59]. In addition,
diﬀerences were observed between the immune modulatory
eﬀects within the group of TZDs tested. This was somewhat
surprising; however, Storer et al. also reported that ciglita-
zone and pioglitazone had no eﬀect on TNF-α or CCL2 pro-
duction by microglia in response to LPS [27], similar to our
ﬁndings in the present study. However, a few discrepancies
between these reports also exist, which might be explained
by the fact that only a single TLR ligand was examined (i.e.,
LPS) and the concentrations of several TZDs exceeded the
maximal dose tested in the current study. In general, only
one TZD, rosiglitazone, exerted rather global eﬀects on the
inﬂammatory mediators examined here, whereas the other
compounds (i.e., ciglitazone, troglitazone, and pioglitazone)
demonstrated diﬀerential eﬀects that were dependent on
the TLR ligand as well as the proinﬂammatory mediator
measured. The reason responsible for these diﬀerences is
not clear but distinct chemical structures of the various
TZDs have been suggested to contribute to their unique
properties [60]. The widespread eﬀects of rosiglitazone on
glial inﬂammatory mediator production are in agreement
with the fact that this TZD has been reported to impact
numerous PPAR-γ isoforms including PPAR-γ1 and PPAR-
γ2, whereas other TZDs have been reported to selectively
target a single PPAR-γ subtype [61, 62]. Other studies have
revealed distinct diﬀerences in the eﬀectiveness of TZD
members in regulating changes in glucose metabolism in
astrocytes[63]andmitochondrialfunction[64].Inaddition,
the EC50 of individual TZD compounds for PPAR-γ does
vary within this group of molecules depending on the
experimental readout examined, which may contribute to
their diﬀerential eﬀects [61, 62]. Alternatively, studies have
shown that the coactivator proteins interacting with PPAR-
γ diﬀer in a ligand-dependent manner [65]. Unfortunately,
there are few reports where comprehensive side-by-side
c o m p a r i s o n sh a v eb e e nm a d ew i t hr e g a r dt ot h ee ﬀects of
various TZD compounds on neuroinﬂammation either in
vitro or in vivo. Making direct comparisons between various
TZDs in disparate models of neuroinﬂammation should
be viewed cautiously since diﬀerences in disease models,
inﬂammatory stimuli, and species examined all have the
potential to inﬂuence the results obtained.
Ourﬁndingsdemonstratingtheinhibitoryeﬀectsof15d-
PGJ2 on TLR ligand-induced glial activation are similar to
those observed following LPS stimulation. Speciﬁcally, 15d-
PGJ2 has been shown to inhibit LPS-induced NO [27–29,
66],TNF-α[27,28,66],andIL-12familymemberexpression
[26] in microglia and/or astrocytes. Importantly, this report
has provided a more comprehensive analysis of the eﬀects
of PPAR-γ agonists on glial activation with the inclusion
of a battery of TLR ligands that would be encountered
during various CNS infectious diseases. Earlier studies have
primarily focused on the immune modulatory eﬀects of
PPAR-γ agonists in response to the TLR4 ligand LPS, and
therefore, this study is also novel from the perspective that
numerous TLR ligands were evaluated.
Interestingly, both 15d-PGJ2 and pioglitazone were
foundtoaugmentCXCL2releasebymicrogliaandastrocytes
in response to speciﬁc TLR ligands. In particular, 15d-PGJ2
enhanced CXCL2 production in response to LPS stimulationCatherine Gurley et al. 9
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Figure 13: Ciglitazone attenuates astrocytic CXCL2 expression in response to several TLR ligands. Primary astrocytes were plated at 1 × 105
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Figure 14: Pioglitazone enhances CXCL2 release by astrocytes
following TLR ligand exposure. Primary astrocytes were plated at
1 × 105 cells/well in 96-well plates and incubated overnight. The
following day, cells were pretreated for 1hour with the indicated
concentrations of pioglitazone prior to the addition of polyI:C,
ﬂagellin, or ssRNA. Cell-conditioned supernatants were collected
at 24hours following TLR ligand exposure, whereupon CXCL2
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presented are representative of two independent experiments.
in both microglia and astrocytes, in agreement with previous
reports [53, 54]. In addition, recent results from our
laboratory have revealed that CXCL2 release was slightly
increased by 15d-PGJ2 and downregulated by ciglitazone in
response to the gram-positive pathogen S. aureus in primary
astrocytes [24], in corroboration with the current report.
Elevated levels of endogenous 15d-PGJ2 have been asso-
ciated with the resolution of inﬂammation in vivo, suggest-
ing that it functions as negative feedback regulator of inﬂam-
matoryresponses[67,68].Thisstudydemonstratesthat15d-
PGJ2 is an eﬀective and selective inhibitor of glial activation
in response to TLR ligands, suggesting that it may be capable
of modulating chronic microglial and astrocyte responses
during the course of CNS infectious diseases. Evidence to
support this concept is provided by our ﬁndings that 15d-
PGJ2 eﬀectively inhibited IL-12 p40 and CCL2 expression
in microglia and astrocytes, two molecules with important
functionsinthediﬀerentiationofCD4+ Th1cellsandmono-
cyte and T cell inﬂux into the infected CNS [52, 55, 56, 69,
70]. It is possible that the downregulation of these mediators
in microglia and astrocytes following 15d-PGJ2 treatment
results in the failure to recruit and/or stimulate Ag-speciﬁc T
cells in the CNS parenchyma. Therefore, preventing chronic
microglial activation by 15d-PGJ2 or synthetic PPAR-γ
agonists may help to resolve inﬂammation earlier, resulting
in less damage to surrounding normal brain parenchyma.
In summary, these studies demonstrate that not all
PPAR-γ agonists are created equal in terms of their ability
to modulate proinﬂammatory mediator release by acti-
vated microglia and astrocytes. Speciﬁcally, diﬀerences were12 PPAR Research
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Figure 15: TZDs exert diﬀerential eﬀects on astrocytic CCL2 production following TLR ligand treatment. Primary astrocytes were plated
at 1 × 105 cells/well in 96-well plates and incubated overnight. The following day, cells were pretreated for 1hour with the indicated
concentrations of pioglitazone (a) or troglitazone, (b) prior to the addition of TLR ligands. Cell-conditioned supernatants were collected
at 24hours following TLR ligand exposure, whereupon CCL2 levels were determined by ELISA (a) and (b). Signiﬁcant diﬀerences between
astrocytes treated with TLR ligands alone versus TLR ligands + TZDs are noted with asterisks (∗P<. 05; ∗∗P<. 001). Results presented are
representative of two independent experiments.
speciﬁc to the type of TLR ligand examined. When consid-
ering the potential utility of PPAR-γ agonists for modulating
pathological inﬂammation typical of several CNS infectious
diseases, critical issues such as the timing and length of
PPAR-γ administration and doses of compound must be
considered. For example, it appears likely that compounds
should be delivered at periods at or nearing pathogen
clearance since a signiﬁcant attenuation of the host immune
response would be counterproductive to infection resolu-
tion. Upon pathogen elimination, PPAR-γ agonists may
minimize damage to surrounding tissue by downregulating
exaggerated CNS immune responses that could be perpetu-
ated by microbial debris (i.e., cell wall fragments such as LPS
and PGN or pathogen nucleic acids) via continued engage-
ment of TLRs. Indeed, recent studies by our laboratory have
revealed that the PPAR-γ agonist ciglitazone demonstrates
beneﬁcial eﬀects with delayed administration in an experi-
mentalbrainabscessmodelasrevealedbyacceleratedabscess
encapsulation and reduction in bacterial burdens [71]. In
addition, recent studies by other groups have revealed ben-
eﬁcial eﬀects of PPAR-γ agonists in other infectious disease
paradigms [72–76]. Therefore, the current study can be used
as a guide to facilitate the selection of PPAR-γ agonists as
candidates for intervention during CNS infectious diseases.
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